These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31731495)

  • 1. The Landscape of Actionable Gene Fusions in Colorectal Cancer.
    Pagani F; Randon G; Guarini V; Raimondi A; Prisciandaro M; Lobefaro R; Di Bartolomeo M; Sozzi G; de Braud F; Gasparini P; Pietrantonio F
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
    Singh H; Li YY; Spurr LF; Shinagare AB; Abhyankar R; Reilly E; Brais LK; Nag A; Ducar MD; Thorner AR; Shapiro GI; Keller RB; Siletti C; Clark JW; Farago AF; Lin JJ; Demetri GD; Gujrathi R; Kulke MH; MacConaill LE; Ligon AH; Sicinska E; Meyerson ML; Meyerhardt JA; Cherniack AD; Wolpin BM; Ng K; Giannakis M; Hornick JL; Cleary JM
    Clin Cancer Res; 2021 Mar; 27(6):1695-1705. PubMed ID: 33414136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTRK fusions in colorectal cancer: clinical meaning and future perspective.
    Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC
    Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
    Taieb J; Jung A; Sartore-Bianchi A; Peeters M; Seligmann J; Zaanan A; Burdon P; Montagut C; Laurent-Puig P
    Drugs; 2019 Sep; 79(13):1375-1394. PubMed ID: 31347092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
    Stintzing S; Stremitzer S; Sebio A; Lenz HJ
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
    Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
    Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging biomarkers in metastatic colorectal cancer.
    Lee MKC; Loree JM
    Curr Oncol; 2019 Nov; 26(Suppl 1):S7-S15. PubMed ID: 31819705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
    Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
    Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
    Bekaii-Saab T; Kim R; Kim TW; O'Connor JM; Strickler JH; Malka D; Sartore-Bianchi A; Bi F; Yamaguchi K; Yoshino T; Prager GW
    Clin Colorectal Cancer; 2019 Mar; 18(1):e117-e129. PubMed ID: 30598357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of RET fusions in advanced colorectal cancer.
    Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
    Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
    Sartore-Bianchi A; Amatu A; Bonazzina E; Stabile S; Giannetta L; Cerea G; Schiavetto I; Bencardino K; Funaioli C; Ricotta R; Cipani T; Schirru M; Gambi V; Palmeri L; Carlo-Stella G; Rusconi F; Di Bella S; Burrafato G; Cassingena A; Valtorta E; Lauricella C; Pazzi F; Gambaro A; Ghezzi S; Marrapese G; Tarenzi E; Veronese S; Truini M; Vanzulli A; Siena S
    Target Oncol; 2017 Aug; 12(4):525-533. PubMed ID: 28669023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
    Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
    Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
    Strickler JH; Wu C; Bekaii-Saab T
    Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.